Tag Archive for: BioPharma

Commit Biologics appoints accomplished R&D executive, Dr Janine Schuurman, to its Board of Directors

/in

Former senior vice president of antibody research at Genmab who has co-invented numerous FDA-approved therapeutic antibodies and as well as its DuoBody® bi-specific antibody platform. Brings decades of experience in developing strong pipelines of antibody-based drugs from platforms, growing scientific teams and managing partnerships with Pharma companies Appointment comes as Commit looks to progress towards […]

Read more

iOnctura reaches new clinical milestones in uveal melanoma

/in

Completed Phase I DIONE-01 study demonstrates clinical activity and long-term safety of roginolisib, a unique allosteric modulator of PI3Kδ Patients with uveal melanoma showed a doubling of overall survival compared to historical controls Site activation ongoing for randomized Phase II OCULE-01 study in uveal melanoma Geneva, Switzerland and Amsterdam, The Netherlands, 11 Dec 2024 – […]

Read more

Poolbeg Pharma plc presents POLB 001 pre-clinical study data at the 66th American Society of Hematology (ASH) Annual Meeting

/in

All doses of POLB 001 significantly reduced clinically observed Cytokine Release Syndrome scores POLB 001 treatment showed statistically significant reductions in key cytokines  Positive results reinforce the use case for POLB 001 in the prevention and treatment of cancer immunotherapy-induced CRS 9 December 2024 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focused […]

Read more

Poolbeg Pharma plc – POLB 001 Patent Granted in United States

/in

Further strengthens Poolbeg’s robust intellectual property portfolio 20 November 2024- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focused on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that the US Patent Office has notified the Company of its official decision to grant Poolbeg’s US Immunomodulator I […]

Read more

Poolbeg Pharma plc – Interim results for the six months to 30 June 2024

/in

Lead development candidate (POLB 001) on track with positive data demonstrating efficacy Independent research endorses potential US$10bn market opportunity for POLB 001 in cancer immunotherapy-induced CRS Patent portfolio significantly strengthened & expanded Continued focus on high value programmes & partnerships to develop & commercialise assets Strong Balance Sheet – cash balance of £10.1m Experienced leadership team with track […]

Read more